123 results
Page 3 of 7
424B5
6k3v5joqqvrvnxb5ec58
20 Jan 21
Prospectus supplement for primary offering
4:24pm
8-K
EX-99.2
40joc7 q6acl39
20 Jan 21
Invitae Announces Proposed Public Offering of Common Stock
4:10pm
8-K
EX-99.1
46268t026rlq
12 Jan 21
Invitae Reports Preliminary 2020 Financial Results of More Than $278 Million in Revenue and More Than 655,000 in Billable Volume
6:06am
8-K
EX-99.2
4lcad 0bvjy
12 Jan 21
Invitae Reports Preliminary 2020 Financial Results of More Than $278 Million in Revenue and More Than 655,000 in Billable Volume
6:06am
8-K/A
EX-99.1
9llr dj3vxgg4rwkcm
23 Nov 20
Consolidated Financial Statements
12:00am
8-K/A
EX-99.2
dcw5lpz rlqjjy4meni6
23 Nov 20
Consolidated Financial Statements
12:00am
8-K/A
EX-99.3
25n9pkd4kk
23 Nov 20
Consolidated Financial Statements
12:00am
8-K
EX-99.1
3uachyeintrbcpy24
5 Nov 20
Invitae Reports $68.7 Million in Revenue Driven by 170,000 Samples Accessioned in the Third Quarter of 2020
4:24pm
8-K
EX-10.3
wc96iywd45x09
5 Oct 20
Invitae Completes Transaction with ArcherDX to Bring Comprehensive Cancer Genetics and Precision Oncology to Patients Worldwide
4:17pm
424B3
rgw1g3pz
28 Aug 20
Prospectus supplement
4:31pm
8-K
EX-99.1
wtkc8zr
4 Aug 20
Invitae Reports $46.2 Million in Revenue Driven by More Than 120,000 Samples Accessioned in the Second Quarter of 2020
4:13pm
425
vzk17dpyvs x3iox
24 Jun 20
Business combination disclosure
5:11pm
8-K
EX-10.1
wrjt9hii
24 Jun 20
Entry into a Material Definitive Agreement
5:08pm
8-K
EX-10.3
4pdc9xb9dx n16j44
24 Jun 20
Entry into a Material Definitive Agreement
5:08pm